BioInvent Resolves on SEK 430 Million Rights Issue, Subject to Approval
BioInvent International’s rights issue of approximately SEK 430 million is subject to approval by an extraordinary general meeting and earlier publication of its January–September 2026 interim report.
Story updates
05:15:34 PM UTC
SquawkNews
BioInvent resolved to launch a SEK 430M rights issue, subject to EGM approval, to fund BI-1808/BI-1206. About SEK 350M (≈81%) is covered by subscriptions and guarantees.Material DetailsContext by AI AnalystThis is a funding step for a clinical-stage biotech refocusing on solid tumor programs, consi…
05:16:45 PM UTC
SquawkNews
BioInvent International AB called a Dec 1, 2026 EGM to approve a new share issue and related articles changes; board size may rise to seven with a proposed new director.Material DetailsContext by AI AnalystThis is a mid-cycle financing step typical for clinical-stage biotech managing runway. A disc…